How will this affect NTII?
Press Release Source: Eisai Inc.
U.S. Food and Drug Administration Approves ARICEPT(R) for Treatment of Severe Alzheimer's Disease
Friday October 13, 7:44 pm ET
First and Only Treatment Approved for the Full Spectrum of Alzheimer's Disease - Mild, Moderate and Severe
TEANECK, N.J. and NEW YORK, Oct. 13 /PRNewswire/ -- Eisai and Pfizer Inc announced today that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for ARICEPT® (donepezil HCl tablets) for treatment of severe Alzheimer's disease (AD). The application was submitted by Eisai Medical Research Inc. (Headquarters: Ridgefield Park, President Mindell Seidlin, MD) on behalf of Eisai Co., Ltd. (Headquarters: Tokyo, President and CEO Haruo Naito) and Eisai Inc. (Headquarters: Teaneck, NJ, Chairman and CEO Hajime Shimizu).
With this approval, ARICEPT becomes the first and only prescription medication to treat the full spectrum of AD (mild, moderate and severe). ARICEPT, which is co-promoted in the United States by Eisai Inc. and Pfizer Inc, has been approved in the United States since 1996 for treatment of mild to moderate AD.
Read the rest of the story: biz.yahoo.com. |
